- We noticed a huge and recent valuation gap between BioLife and CryoPort, both operating in the regenerative medicine market supplying storage media and distribution solutions.
- We surmised this was mostly due to investors discounting BioLife’s distribution business, SAVSU.
- Now that BioLife has exercised its option to buy the remaining 56% of SAVSU, it is publicly signaling progress and there are even fewer reasons for the huge valuation discount.
BioLife Buying The Remaining 56% Of SAVSU Is A Huge Positive Signal
July 16th, 2019 · No Comments